Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05790668 · ClinicalTrials.gov registry record · NA

Motivational Refinements for Facilitating Reinforcement Schedule Thinning

A NA study of Decreasing Destructive Behavior and Increasing Functional Communicative Behavior, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
2
Study locations

NCT05790668: Recruiting NA study of Decreasing Destructive Behavior and Increasing Functional Communicative Behavior, sponsored by Rutgers, The State University of New Jersey.

NCT05790668 is a NA study of Decreasing Destructive Behavior and Increasing Functional Communicative Behavior that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05790668, a NA study of Decreasing Destructive Behavior and Increasing Functional Communicative Behavior, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

Destructive behavior represents a comorbid condition of developmental disability for which risk increases with intellectual disability severity, communication deficits, and co-occurring autism spectrum disorder. Destructive behavior, such as self-injurious behavior and aggression, causes harm to the child and others and increases the risk for institutionalization, social isolation, physical restraint, medication overuse, and abuse. Clinicians have used functional analyses to identify the variables that reinforce destructive behavior and to develop effective, function-based treatments. Functional communication training (FCT) is an empirically supported, function-based treatment that decreases destructive behavior. Using FCT, the clinician teaches the child to use a functional communication response (FCR) to request the reinforcer maintaining destructive behavior, while placing destructive behavior on extinction. For example, if functional analysis results showed that attention reinforced destructive behavior, the clinician would provide attention when the child used the FCR ("Play with me, please") and would not provide attention for destructive behavior. Two limitations of FCT are that (a) schedules of reinforcement maintaining the FCR must often be thinned gradually to levels that are practical for caregivers to implement consistently in the home and in the community, and (b) this necessary process of reinforcement schedule thinning regularly causes destructive behavior to increase following initially effective treatment, a form of treatment relapse called resurgence. The current project aims to improve these limitations of FCT by (a) hastening the process of reinforcement schedule thinning by removing unnecessary schedule-thinning steps using the results of a progressive interval assessment and (b) mitigating the resurgence of destructive behavior by providing stimuli that highly compete with the reinforcer maintaining destructive behavior. The investigators will

Primary Outcome

The primary outcome measure is responses per minute of destructive behavior. The investigators will calculate this outcome by dividing the total number of destructive responses per session by the total number of minutes spent in session.

Interventions

  • BEHAVIORAL Traditional Schedule Thinning
  • BEHAVIORAL PIA-Informed Schedule Thinning
  • BEHAVIORAL PIA-Informed Schedule Thinning with Competing Stimuli

Study Locations (2)

New Jersey

  • Douglass Developmental Disabilities Center - New Brunswick
  • Rutgers University Center for Autism Research, Education, and Services - Somerset

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-10-24
Est. Completion 2028-08-31
Phase NA

What NCT05790668 shows while recruiting

NCT05790668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Decreasing Destructive Behavior appearing as the primary indexed condition, and to 3 interventions - of which Traditional Schedule Thinning is the first listed.

NCT05790668 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT05790668 about?

NCT05790668 is a clinical study titled "Motivational Refinements for Facilitating Reinforcement Schedule Thinning". Destructive behavior represents a comorbid condition of developmental disability for which risk increases with intellectual disability severity, communication deficits, and co-occurring autism spectrum disorder. Destructive behavior, such as self-injurious behavior and aggression, causes harm to the...

What is the current status of trial NCT05790668?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-10-24. Estimated completion is 2028-08-31.

What conditions does trial NCT05790668 study?

This clinical trial studies the following conditions: Decreasing Destructive Behavior, Increasing Functional Communicative Behavior.

What interventions are being tested in trial NCT05790668?

The interventions under investigation include: Traditional Schedule Thinning (BEHAVIORAL), PIA-Informed Schedule Thinning (BEHAVIORAL), PIA-Informed Schedule Thinning with Competing Stimuli (BEHAVIORAL).

Who is sponsoring clinical trial NCT05790668?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05790668 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT05790668's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05790668, the US trial registry maintained by the National Library of Medicine. NCT05790668 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.